A compound with benzyloxy aromatic ring structure, its preparation method and use

A compound and alkyl technology, applied in the field of drug synthesis, can solve problems such as poor stability, easy immunogenicity, and high production costs

Active Publication Date: 2021-11-05
SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI +1
View PDF13 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, antibody drugs have their own characteristics, such as high production costs, poor stability, need to be administered by injection, and are prone to immunogenicity, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A compound with benzyloxy aromatic ring structure, its preparation method and use
  • A compound with benzyloxy aromatic ring structure, its preparation method and use
  • A compound with benzyloxy aromatic ring structure, its preparation method and use

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0241] The present invention also provides a preparation method of a pharmaceutical composition, comprising the steps of: mixing a pharmaceutically acceptable carrier with the compound of general formula (I) or its crystal form, pharmaceutically acceptable salt, hydrate or The solvates are mixed to form a pharmaceutical composition.

[0242] The present invention also provides a treatment method, which includes the step of: administering the compound of general formula (I) described in the present invention, its stereoisomer, enantiomer or pharmaceutically acceptable salt, or administer the pharmaceutical composition of the present invention for inhibiting PD1-PDL1 interaction.

[0243] The preparation of formula I compound

[0244] Methods of preparing compounds of Formula I are described in the following Schemes and Examples. Starting materials and intermediates were purchased from commercial sources, prepared by known procedures, or otherwise illustrated. In some cases, ...

Embodiment 1

[0380] Example 1: Synthesis of N-(3-((2-((3-cyanobenzyl)oxy)-4-((3-(2,3-dihydrobenzo[b][1,4] Dioxin-6-yl)-2-methylbenzyl)oxy)-5-methylbenzyl)(methyl)amino)propyl)but-2-yneamide (ZA89)

[0381]

[0382] Step 1: Synthesis of (3-bromo-2-methylphenyl)methanol (ZA01)

[0383] Dissolve 3-bromo-2-methylbenzoic acid (5.0g, 23.4mmol) in dry THF (tetrahydrofuran) (100ml), cool down in an ice-water bath, and then add LiAlH 4 (1.06g, 27.9mmol), react overnight at room temperature. After the reaction, the reaction solution was poured into saturated NaHCO 3 Quenched in , filtered, rinsed with dichloromethane (DCM), and the organic phase was dried with anhydrous sodium sulfate and then spin-dried to obtain the target product (2.0 g). 1 H NMR (400MHz, Chloroform-d) δ7.53(dd, J=1.2,8.0Hz,1H),7.36–7.29(m,1H),7.07(t,J=7.8Hz,1H),4.72(s, 2H), 2.43(s, 3H).

[0384] Step 2: Synthesis of (3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylphenyl)methanol (ZA03)

[0385] Dissolve ZA01 (198mg, 1....

Embodiment 2

[0394] Example 2: Synthesis of 3-((5-((3-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)-2-methylbenzyl )oxy)-4-methyl-2-((((2S,3R,4R,5R)-2,3,4,5,6-pentahydroxyhexyl)amino)methyl)phenoxy)methyl ) Benzonitrile (ED01)

[0395]

[0396] ZA80 (0.08mmol, 40mg), D-glucosamine (0.33mmol, 60mg) were dissolved in THF (4mL) and methanol (4mL), stirred at room temperature for 1 hour, and NaBH was added 4 (80mg, 2.1mmol), stirred overnight. After the reaction was completed, it was quenched with dilute hydrochloric acid, concentrated to obtain the crude product, and the crude product was purified by reverse liquid phase to obtain the trifluoroacetate (3.1 mg) of the target compound. 1 H NMR (400M, MeOD-d4): 7.90(s, 1H), 7.82(d, J=7.98Hz, 1H), 7.71(d, J=7.84Hz, 1H), 7.59(t, J=7.70Hz, 1H), 7.34(dd, J=7.07, 1.64Hz, 1H), 7.24-7.14(m, 3H), 6.88(d, J=8.03Hz, 1H), 6.80(s, 1H), 6.76-6.71(m ,2H),5.30(s,3H),5.15(s,3H),4.28(s,4H),4.21(q,J=12.34Hz,2H),4.11-4.05(m,1H),3.85(dd, J=4.44,1.36Hz,1H),3.77(dd,J...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a compound with benzyloxy aromatic ring structure represented by general formula (I), its stereoisomer, enantiomer or pharmaceutically acceptable salt thereof, its preparation method, and its pharmaceutical combination objects and their uses. The compound represented by the general formula (I) can be used to prepare small molecule inhibitors of PD1 / PD-L1 interaction, which can be used to prevent and / or treat diseases related to PD1 / PD-L1 interaction, especially cancer , such as, inter alia, non-small cell lung cancer, small cell lung cancer, melanoma, head and neck cancer, kidney cancer, bladder cancer, locally advanced or metastatic urothelial cancer, breast cancer, cervical cancer, metastatic Merkel cell carcinoma, prostate cancer Carcinoma, liver cancer, colon cancer, gastric cancer, multiple myeloma, mantle cell lymphoma, diffuse large B-cell lymphoma liver cancer, Hodgkin's lymphoma, chronic lymphocytic leukemia, squamous cell carcinoma and other cancers.

Description

technical field [0001] The invention belongs to the field of pharmaceutical synthesis, and specifically relates to a class of compounds with a benzyloxy aromatic ring structure, stereoisomers, enantiomers or pharmaceutically acceptable salts thereof, a preparation method and application thereof. Background technique [0002] Under normal circumstances, immune cells in the human body, such as CD4 / CD8+ T cells, have a killing effect on cancer cells, so that people with normal immune functions can avoid cancer. However, after the PD-1 (Programmed death 1) receptor on the surface of the T cell membrane is bound by the PD-L1 (Programmed death-ligand 1) protein expressed by the tumor cell, the immune function of the T cell is severely inhibited, and the immune function cannot be performed normally. Its ability to inhibit cancer cell proliferation is severely impaired (the New England Journal of Medicine, 2012, 366, 2517). Using the PD-L1 protein of tumor cells to bind to the PD-1...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): C07D319/18C07F9/655C07D407/12C07D405/12C07C255/54C07D213/69C07D213/85C07D405/14A61K31/357A61K31/665A61K31/497A61K31/4433A61K31/277A61K31/44A61K31/444A61P35/00A61P35/02A61P31/04A61P31/10A61P31/18A61P31/14A61P31/20A61P31/22A61P31/16
CPCA61P31/04A61P31/10A61P31/14A61P31/16A61P31/18A61P31/20A61P31/22A61P35/00A61P35/02C07C255/54C07D213/69C07D213/85C07D319/18C07D405/12C07D405/14C07D407/12C07F9/65522A61K31/047A61K31/277A61K31/357A61K31/36A61K31/44A61K31/4433A61K31/444A61K31/4545A61K31/497A61K31/665C07D213/84C07D319/10C07D413/12C07D413/14C07F9/655C07H15/18C07H15/26
Inventor 赵玉军朱棣周飞龙严子琴刘成龙张希晨
Owner SHANGHAI INST OF MATERIA MEDICA CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap